vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Claritev Corp (CTEV). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -32.7%, a 32.0% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs 0.7%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 2.5%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AVNS vs CTEV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $246.6M |
| Net Profit | $-1.3M | $-80.6M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | -3.1% |
| Net Margin | -0.7% | -32.7% |
| Revenue YoY | 0.7% | 6.2% |
| Net Profit YoY | 99.7% | 41.6% |
| EPS (diluted) | $-0.02 | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $246.6M | ||
| Q3 25 | $177.8M | $246.0M | ||
| Q2 25 | $175.0M | $241.6M | ||
| Q1 25 | $167.5M | $231.3M | ||
| Q4 24 | $179.6M | $232.1M | ||
| Q3 24 | $170.4M | $230.5M | ||
| Q2 24 | $171.7M | $233.5M | ||
| Q1 24 | $166.1M | $234.5M |
| Q4 25 | $-1.3M | $-80.6M | ||
| Q3 25 | $-1.4M | $-69.8M | ||
| Q2 25 | $-76.8M | $-62.6M | ||
| Q1 25 | $6.6M | $-71.3M | ||
| Q4 24 | $-397.3M | $-138.0M | ||
| Q3 24 | $4.3M | $-391.4M | ||
| Q2 24 | $1.8M | $-576.7M | ||
| Q1 24 | $-900.0K | $-539.7M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | -3.1% | ||
| Q3 25 | 0.1% | 4.1% | ||
| Q2 25 | -42.6% | 6.9% | ||
| Q1 25 | 6.1% | 4.2% | ||
| Q4 24 | -233.0% | -17.8% | ||
| Q3 24 | 7.0% | -146.7% | ||
| Q2 24 | 3.7% | -224.4% | ||
| Q1 24 | 2.4% | -207.4% |
| Q4 25 | -0.7% | -32.7% | ||
| Q3 25 | -0.8% | -28.4% | ||
| Q2 25 | -43.9% | -25.9% | ||
| Q1 25 | 3.9% | -30.8% | ||
| Q4 24 | -221.2% | -59.4% | ||
| Q3 24 | 2.5% | -169.8% | ||
| Q2 24 | 1.0% | -247.0% | ||
| Q1 24 | -0.5% | -230.1% |
| Q4 25 | $-0.02 | $-4.88 | ||
| Q3 25 | $-0.03 | $-4.23 | ||
| Q2 25 | $-1.66 | $-3.81 | ||
| Q1 25 | $0.14 | $-4.38 | ||
| Q4 24 | $-8.64 | $-8.49 | ||
| Q3 24 | $0.09 | $-24.25 | ||
| Q2 24 | $0.04 | $-35.78 | ||
| Q1 24 | $-0.02 | $-33.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $16.8M |
| Total DebtLower is stronger | $90.3M | $4.6B |
| Stockholders' EquityBook value | $778.2M | $-173.9M |
| Total Assets | $1.1B | $4.9B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $16.8M | ||
| Q3 25 | $70.5M | $39.2M | ||
| Q2 25 | $90.3M | $56.4M | ||
| Q1 25 | $97.0M | $23.1M | ||
| Q4 24 | $107.7M | $16.8M | ||
| Q3 24 | $89.0M | $86.6M | ||
| Q2 24 | $92.2M | $48.8M | ||
| Q1 24 | $75.8M | $58.7M |
| Q4 25 | $90.3M | $4.6B | ||
| Q3 25 | $93.4M | $4.5B | ||
| Q2 25 | $95.7M | $4.5B | ||
| Q1 25 | $98.0M | $4.5B | ||
| Q4 24 | $125.3M | $4.5B | ||
| Q3 24 | $152.6M | $4.5B | ||
| Q2 24 | $164.9M | $4.5B | ||
| Q1 24 | $167.2M | $4.5B |
| Q4 25 | $778.2M | $-173.9M | ||
| Q3 25 | $778.0M | $-101.8M | ||
| Q2 25 | $776.3M | $-39.9M | ||
| Q1 25 | $839.4M | $14.8M | ||
| Q4 24 | $828.5M | $84.0M | ||
| Q3 24 | $1.2B | $207.6M | ||
| Q2 24 | $1.2B | $603.4M | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $1.1B | $4.9B | ||
| Q3 25 | $1.1B | $5.0B | ||
| Q2 25 | $1.0B | $5.1B | ||
| Q1 25 | $1.1B | $5.1B | ||
| Q4 24 | $1.2B | $5.2B | ||
| Q3 24 | $1.7B | $5.3B | ||
| Q2 24 | $1.7B | $5.7B | ||
| Q1 24 | $1.7B | $6.4B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | 304.87× | ||
| Q4 24 | 0.15× | 53.67× | ||
| Q3 24 | 0.12× | 21.73× | ||
| Q2 24 | 0.13× | 7.48× | ||
| Q1 24 | 0.14× | 3.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $66.3M |
| Free Cash FlowOCF − Capex | $21.3M | $36.4M |
| FCF MarginFCF / Revenue | 11.8% | 14.8% |
| Capex IntensityCapex / Revenue | 3.8% | 12.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $66.3M | ||
| Q3 25 | $14.0M | $19.9M | ||
| Q2 25 | $6.8M | $61.2M | ||
| Q1 25 | $25.7M | $-30.1M | ||
| Q4 24 | $57.9M | $-33.4M | ||
| Q3 24 | $23.0M | $72.8M | ||
| Q2 24 | $27.8M | $18.5M | ||
| Q1 24 | $-8.0M | $49.7M |
| Q4 25 | $21.3M | $36.4M | ||
| Q3 25 | $7.0M | $-16.3M | ||
| Q2 25 | $-4.2M | $36.6M | ||
| Q1 25 | $19.0M | $-68.9M | ||
| Q4 24 | $53.1M | $-63.8M | ||
| Q3 24 | $20.0M | $41.1M | ||
| Q2 24 | $21.9M | $-7.0M | ||
| Q1 24 | $-12.1M | $19.2M |
| Q4 25 | 11.8% | 14.8% | ||
| Q3 25 | 3.9% | -6.6% | ||
| Q2 25 | -2.4% | 15.2% | ||
| Q1 25 | 11.3% | -29.8% | ||
| Q4 24 | 29.6% | -27.5% | ||
| Q3 24 | 11.7% | 17.8% | ||
| Q2 24 | 12.8% | -3.0% | ||
| Q1 24 | -7.3% | 8.2% |
| Q4 25 | 3.8% | 12.1% | ||
| Q3 25 | 3.9% | 14.7% | ||
| Q2 25 | 6.3% | 10.2% | ||
| Q1 25 | 4.0% | 16.8% | ||
| Q4 24 | 2.7% | 13.1% | ||
| Q3 24 | 1.8% | 13.8% | ||
| Q2 24 | 3.4% | 10.9% | ||
| Q1 24 | 2.5% | 13.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CTEV
Segment breakdown not available.
